SAN DIEGO, October 25 — A four-year patent litigation suit between Hyseq and Affymetrix has come to a strange and surprising end. The two companies announced on Thursday that they have agreed to dismiss all pending suits in the US District Court, to cease their involvement in pending patent interference proceedings before the US Patent and Trade Office, and to form a joint venture. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.